153 related articles for article (PubMed ID: 16856041)
1. Purine antagonists for chronic lymphocytic leukaemia.
Steurer M; Pall G; Richards S; Schwarzer G; Bohlius J; Greil R
Cochrane Database Syst Rev; 2006 Jul; 2006(3):CD004270. PubMed ID: 16856041
[TBL] [Abstract][Full Text] [Related]
2. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Steurer M; Pall G; Richards S; Schwarzer G; Bohlius J; Greil R;
Cancer Treat Rev; 2006 Aug; 32(5):377-89. PubMed ID: 16793209
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab for patients with chronic lymphocytic leukaemia.
Skoetz N; Bauer K; Elter T; Monsef I; Roloff V; Hallek M; Engert A
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008078. PubMed ID: 22336834
[TBL] [Abstract][Full Text] [Related]
4. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
5. Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Mulligan SP; Karlsson K; Strömberg M; Jønsson V; Gill D; Hammerström J; Hertzberg M; McLennan R; Uggla B; Norman J; Wallvik J; Sundström G; Johansson H; Brandberg Y; Liliemark J; Juliusson G;
Leuk Lymphoma; 2014 Dec; 55(12):2769-77. PubMed ID: 24524339
[TBL] [Abstract][Full Text] [Related]
6. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
Kimby E; Brandt L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):224-30. PubMed ID: 11441934
[TBL] [Abstract][Full Text] [Related]
7. Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Bergmann L
Leukemia; 1997 Apr; 11 Suppl 2():S29-34. PubMed ID: 9178835
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment strategies in chronic lymphocytic leukemia.
Weiss MA
Curr Oncol Rep; 2001 May; 3(3):217-22. PubMed ID: 11296131
[TBL] [Abstract][Full Text] [Related]
9. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
10. Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
Kay NE
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S50-4. PubMed ID: 16549115
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
12. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
14. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Robak T; Kasznicki M
Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
[TBL] [Abstract][Full Text] [Related]
15. The role of nucleoside analogues in the treatment of chronic lymphocytic leukemia-lessons learned from prospective randomized trials.
Robak T
Leuk Lymphoma; 2002 Mar; 43(3):537-48. PubMed ID: 12002757
[TBL] [Abstract][Full Text] [Related]
16. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N; Will A; Monsef I; Brillant C; Engert A; von Tresckow B
Cochrane Database Syst Rev; 2017 May; 5(5):CD007941. PubMed ID: 28541603
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukemia treatment.
Dighiero G
Hematol Cell Ther; 1997 Nov; 39 Suppl 1():S31-40. PubMed ID: 9471059
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Kantarjian H; Robertson LB; Koller C; Beran M; Estey E
Leuk Lymphoma; 1993; 10 Suppl():139-45. PubMed ID: 8097653
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine versus chlorambucil: is the debate over?
Rai KR; Hollweg A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S7-9. PubMed ID: 22035752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
